These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 1689694)

  • 1. Experimental treatment of autoimmune MRL-lpr/lpr mice with immunosuppressive compound FK506.
    Yamamoto K; Mori A; Nakahama T; Ito M; Okudaira H; Miyamoto T
    Immunology; 1990 Feb; 69(2):222-7. PubMed ID: 1689694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of FTY720 in MRL-lpr/lpr mice: therapeutic potential in systemic lupus erythematosus.
    Okazaki H; Hirata D; Kamimura T; Sato H; Iwamoto M; Yoshio T; Masuyama J; Fujimura A; Kobayashi E; Kano S; Minota S
    J Rheumatol; 2002 Apr; 29(4):707-16. PubMed ID: 11950011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amelioration of autoimmune nephritis by imatinib in MRL/lpr mice.
    Sadanaga A; Nakashima H; Masutani K; Miyake K; Shimizu S; Igawa T; Sugiyama N; Niiro H; Hirakata H; Harada M
    Arthritis Rheum; 2005 Dec; 52(12):3987-96. PubMed ID: 16320345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 5-Azacytidine inhibits the lpr gene-induced lymphadenopathy and acceleration of lupus-like syndrome in MRL/MpJ-lpr/lpr mice.
    Yoshida H; Yoshida M; Merino R; Shibata T; Izui S
    Eur J Immunol; 1990 Sep; 20(9):1989-93. PubMed ID: 1698637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CS-A therapy in MRL-lpr/lpr mice: amelioration of immunopathology despite autoantibody production.
    Mountz JD; Smith HR; Wilder RL; Reeves JP; Steinberg AD
    J Immunol; 1987 Jan; 138(1):157-63. PubMed ID: 3537128
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of autoimmune MRL/Ipr mice with monoclonal antibody to Thy-1.2: a single injection has sustained effects on lymphoproliferation and renal disease.
    Seaman WE; Wofsy D; Greenspan JS; Ledbetter JA
    J Immunol; 1983 Apr; 130(4):1713-8. PubMed ID: 6187819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beneficial effects of long-term treatment with SK&F 105685 in murine lupus nephritis.
    Albrightson-Winslow CR; Brickson B; King A; Olivera D; Short B; Saunders C; Badger AM
    J Pharmacol Exp Ther; 1990 Oct; 255(1):382-7. PubMed ID: 2145424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abrogation of skin disease in LUPUS-prone MRL/FASlpr mice by means of a novel tylophorine analog.
    Choi JY; Gao W; Odegard J; Shiah HS; Kashgarian M; McNiff JM; Baker DC; Cheng YC; Craft J
    Arthritis Rheum; 2006 Oct; 54(10):3277-83. PubMed ID: 17009262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-Ccl2 Spiegelmer permits 75% dose reduction of cyclophosphamide to control diffuse proliferative lupus nephritis and pneumonitis in MRL-Fas(lpr) mice.
    Kulkarni O; Eulberg D; Selve N; Zöllner S; Allam R; Pawar RD; Pfeiffer S; Segerer S; Klussmann S; Anders HJ
    J Pharmacol Exp Ther; 2009 Feb; 328(2):371-7. PubMed ID: 18997060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. G-rich DNA suppresses systemic lupus.
    Patole PS; Zecher D; Pawar RD; Gröne HJ; Schlöndorff D; Anders HJ
    J Am Soc Nephrol; 2005 Nov; 16(11):3273-80. PubMed ID: 16176997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of a novel immunosuppressant, FK506, on spontaneous lupus nephritis in MRL/MpJ-lpr/lpr mice.
    Entani C; Izumino K; Iida H; Fujita M; Asaka M; Takata M; Sasayama S
    Nephron; 1993; 64(3):471-5. PubMed ID: 7688103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IFN-gamma receptor signaling is essential for the initiation, acceleration, and destruction of autoimmune kidney disease in MRL-Fas(lpr) mice.
    Schwarting A; Wada T; Kinoshita K; Tesch G; Kelley VR
    J Immunol; 1998 Jul; 161(1):494-503. PubMed ID: 9647261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autoimmune kidney disease in MRL/Mp-lpr/lpr mice inhibited by OK-432, a streptococcal preparation.
    Mihara M; Ohsugi Y
    Clin Exp Immunol; 1989 Oct; 78(1):102-7. PubMed ID: 2805413
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protection against autoimmune nephritis in MyD88-deficient MRL/lpr mice.
    Sadanaga A; Nakashima H; Akahoshi M; Masutani K; Miyake K; Igawa T; Sugiyama N; Niiro H; Harada M
    Arthritis Rheum; 2007 May; 56(5):1618-28. PubMed ID: 17469144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Studies of lymphoproliferation in MRL-lpr/lpr mice.
    Smathers PA; Santoro TJ; Chused TM; Reeves JP; Steinberg AD
    J Immunol; 1984 Oct; 133(4):1955-61. PubMed ID: 6332142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Opposite effects of low and high dose supplementation of vitamin E on survival of MRL/lpr mice.
    Hsieh CC; Lin BF
    Nutrition; 2005 Sep; 21(9):940-8. PubMed ID: 16054337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IFN-gamma is essential for the development of autoimmune glomerulonephritis in MRL/Ipr mice.
    Haas C; Ryffel B; Le Hir M
    J Immunol; 1997 Jun; 158(11):5484-91. PubMed ID: 9164971
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Control of lymphoproliferative and autoimmune disease in MRL-lpr/lpr mice by brequinar sodium: mechanisms of action.
    Xu X; Gong H; Blinder L; Shen J; Williams JW; Chong AS
    J Pharmacol Exp Ther; 1997 Nov; 283(2):869-75. PubMed ID: 9353408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of thymectomy or androgen administration upon the autoimmune disease of MRL/Mp-lpr/lpr mice.
    Steinberg AD; Roths JB; Murphy ED; Steinberg RT; Raveche ES
    J Immunol; 1980 Aug; 125(2):871-3. PubMed ID: 7391583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of lymphadenopathy in MRL-lpr/lpr mice by blocking peripheral lymph node homing with Mel-14 in vivo.
    Mountz JD; Gause WC; Finkelman FD; Steinberg AD
    J Immunol; 1988 May; 140(9):2943-9. PubMed ID: 2834447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.